Conflict of interest statement
Noboru Asada has received honoraria from AbbVie, Astellas Pharma, Chugai Pharmaceutical, Celgene, Eisai, Kyowa Kirin, Otsuka Pharmaceutical, Novartis Pharma and Sanofi. Chikashi Yoshida has received research funding from Bristol-Myers Squibb and honoraria from Bristol-Myers Squibb, Novartis Pharma, Pfizer Japan, Otsuka Pharmaceutical, AbbVie, Janssen Pharmaceutical, Nippon Shinyaku and Chugai Pharmaceutical, Takeda Pharmaceutical and Ono Pharmaceutical. Kensuke Usuki has received research funding from Astellas-Amgen-Biopharma, Otsuka Pharmaceutical, Apellis Pharmaceuticals, SymBio Pharmaceuticals, Takeda Pharmaceutical, Nippon Shinyaku, Novartis Pharma, AbbVie, Janssen Pharmaceutical, Bristol-Myers Squibb, Ono Pharmaceutical, Chugai Pharmaceutical, Daiichi Sankyo, MSD, Astellas Pharma, Alexion Pharmaceuticals, Kyowa-Kirin, Gilead Sciences, Pfizer, Incyte, SymBio Pharmaceuticals, Celgene, Sumitomo Dainippon Pharma, Mundipharma International, Yakult, Eisai and Celgene; honoraria from Novartis Pharma, Astellas Pharma, Alexion Pharmaceuticals, Eisai, MSD, Otsuka Pharmaceutical, Ono Pharmaceutical, Kyowa-Kirin, Celgene, Daiichi Sankyo, Takeda Pharmaceutical, Nippon-Shinyaku, PharmaEssentia, Bristol-Myers Squibb, Yakult, Sanofi, Pfizer, AbbVie and Chugai Pharmaceutical; and has served on consulting bureaus for Alexion Pharmaceuticals, SymBio Pharmaceuticals, Nippon Shinyaku, Otsuka Pharmaceutical, Chugai Pharmaceutical, Sanofi, Takeda Pharmaceutical, Kyowa-Kirin, Astellas Pharma and Alnylam Japan. Kenichi Ishizawa has received research funding from Novartis Pharma, AbbVie, Bayer, SymBio Pharmaceuticals, Pfizer, Sanofi and Otsuka Pharmaceutical; honoraria from Takeda Pharmaceutical, Celgene, Ono Pharmaceutical, Novartis Pharma, Chugai Pharmaceutical, Eisai, IQVIA Services Japan, MSD, Kyowa Kirin, Janssen Pharmaceutical and Micron. Toshihiro Miyamoto has received honoraria from AbbVie, Janssen Pharmaceutical, Bristol-Myers Squibb, Otsuka Pharmaceutical, Astellas Pharma and MSD. Hiroatsu Iida has received research funding from Chugai Pharmaceutical; honoraria from Janssen Pharmaceutical, AbbVie, Astellas Pharma, Chugai Pharmaceutical and Novartis Pharma. Nobuaki Dobashi has received research finding from Astellas Pharma, Chugai Pharmaceutical, Daiichi Sankyo, Kyowa Kirin, Otsuka Pharmaceutical, AbbVie, Takeda Pharmaceutical, Ono Pharmaceutical, Bristol-Myers Squibb, Pfizer and Japan Agency for Medical Research and Development; honoraria from Otsuka Pharmaceutical and Nippon Shinyaku and paid expert testimony from Otsuka Pharmaceutical. Sumiko Okubo, Hideyuki Honda, Tomomi Soshin, Yasuko Nishimura and Atsuko Tsutsui are employees of AbbVie and may own stock or possess stock options. Harumi Mukai was the former employee of AbbVie (currently affiliated with Moderna Japan). Kazuhito Yamamoto reports grants and personal fees from AbbVie, grants and personal fees from AstraZeneca, grants and personal fees from Bristol-Myers Squibb/Celgene, grants and personal fees from Chugai Pharmaceutical, grants and personal fees from Eisai, grants from IQVIA/Genmab, grants and personal fees from Meiji Seika Pharma, personal fees from Nippon Shinyaku, grants and personal fees from Novartis Pharma, grants and personal fees from Ono Pharmaceutical, grants and personal fees from Otsuka Pharmaceutical, grants from Solasia Pharma, personal fees from SymBio Pharmaceuticals, grants and personal fees from Takeda Pharmaceutical, grants from Yakult, grants and personal fees from Zenyaku Kogyo, personal fees from HUYA Bioscience International/IQVIA Services Japan, personal fees from Janssen Pharmaceutical, personal fees from Kyowa Kirin, personal fees from Micron, personal fees from MSD, personal fees from Sanofi, grants from Incyte, personal fees from Pfizer and personal fees from Nippon Kayaku, outside the submitted work. Jun Ando has received honoraria from Novartis Pharma and AbbVie and research funding from AbbVie and Daiichi Sankyo. Atsushi Shinagawa and Satoru Takada have nothing to disclose.